









Markets
/
Stocks
/
nasdaq-pulm
/

Pulmatrix Inc

PULM

4.980USD

+0.080+1.63%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

18.19MMarket Cap

LossP/E TTM



Pulmatrix Inc

4.980

+0.080+1.63%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

230 / 506

Overall Ranking

370 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 28.58% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.81M.

Undervalued

The company’s latest PE is -2.29, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 356.36K shares, decreasing 17.38% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 110.82K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.80, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 73.34%.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.68

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.26, which is -76.96% below the recent high of -0.52 and 63.20% above the recent low of -0.83.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 230/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.10, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.24 and the support level at 4.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.10

Change

1.41

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.100

Neutral

RSI(14)

48.688

Neutral

STOCH(KDJ)(9,3,3)

53.057

Neutral

ATR(14)

0.194

High Vlolatility

CCI(14)

33.453

Neutral

Williams %R

38.889

Buy

TRIX(12,20)

-0.076

Sell

StochRSI(14)

33.100

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

5.010

Sell

MA10

4.964

Buy

MA20

4.910

Buy

MA50

5.229

Sell

MA100

6.219

Sell

MA200

6.518

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 9.76%, representing a quarter-over-quarter increase of 2.97%. The largest institutional shareholder is James Simons, holding a total of 110.82K shares, representing 3.03% of shares outstanding, with 1.56% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Renaissance Technologies LLC

Star Investors

108.92K

-0.18%

SBI Securities Co., Ltd.

52.36K

-20.90%

BlackRock Institutional Trust Company, N.A.

54.90K

The Vanguard Group, Inc.

Star Investors

42.40K

+20.87%

Geode Capital Management, L.L.C.

40.37K

+9.48%

State Street Global Advisors (US)

13.95K

Higgins (Michael J)

7.83K

Dimensional Fund Advisors, L.P.

6.25K

+27.72%

UBS Financial Services, Inc.

1.16K

-76.52%

Batycky (Richard P. Ph.D.)

4.69K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.20, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.65. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.